Even when the disease is caught early, breast cancer recurrence is relatively common — and for survivors, the prospect can be daunting.

A drug developed by Swiss pharmaceutical-maker Novartis has now been shown to reduce this risk by a quarter in a large group of early-stage survivors, offering patients new hope.

Results from a clinical trial were presented Friday at the American Society of Clinical Oncology's (ASCO) annual meeting.